` ALERS (Eurobio Scientific SA) vs DAX Index Comparison - Alpha Spread

ALERS
vs
D
DAX Index

Over the past 12 months, ALERS has underperformed DAX Index, delivering a return of -5% compared to the DAX Index's +24% growth.

Stocks Performance
ALERS vs DAX Index

Loading
ALERS
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ALERS vs DAX Index

Loading
ALERS
DAX Index
Difference
www.alphaspread.com

Performance By Year
ALERS vs DAX Index

Loading
ALERS
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Eurobio Scientific SA vs Peers

DAX Index
ALERS
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Eurobio Scientific SA
Glance View

Market Cap
241m EUR
Industry
Biotechnology

Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.

ALERS Intrinsic Value
21.27 EUR
Overvaluation 12%
Intrinsic Value
Price
Back to Top